Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan.

Shintaro Sagami Kiyohiro Nishikawa Fumika YamadaYasuo SuzukiMamoru Watanabe Toshifumi Hibi

Published in: Journal of gastroenterology and hepatology (2021)

The results of long-term PMS of CT-P13 compared with external reference data from an administrative database suggested that the biosimilar and its originator were comparably useful in real-world clinical practice.

Keyphrases

clinical practice
electronic health record
image quality
computed tomography
dual energy
contrast enhanced
big data
magnetic resonance imaging
positron emission tomography
emergency department
magnetic resonance
adverse drug
machine learning
artificial intelligence